Brief: Tianjin Development Says FY Total Operating Income For Tianjin Lisheng Pharmaceutical RMB1.15 Bln
March 24 (Reuters) - Tianjin Lisheng Pharmaceutical Co
Ltd 002393.SZ :
* FY TOTAL OPERATING INCOME FOR TIANJIN LISHENG
PHARMACEUTICAL
RMB1.15 BILLION VERSUS RMB1.09 BILLION
* FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG
PHARMACEUTICAL
RMB93.6 MILLION VERSUS RMB122.1 MILLION
* BOD OF LISHENG PHARMACEUTICAL PROPOSED TO DISTRIBUTE A
CASH
DIVIDEND OF RMB3.00 (TAX INCLUSIVE) FOR EVERY 10 SHARES
Source text for Eikon: ID:nHKS9F5ZR6
Further company coverage: 002393.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tianjin Development Holdings
See all newsHong Kong's Tianjin Development HY revenue on lower pharmaceutical, utilities sales
Brief: Tianjin Development Says Teng Fei Resigns As Chairman And Executive Director
Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
Brief: Tianjin Development Says Tianjin Lisheng Pharmaceutical QTRLY Operating Income RMB 332.28 Mln